Contact this trialFirst, we need to learn more about you.
Immunotherapy
Sacituzumab Tirumotecan + Pembrolizumab for Lung Cancer
Recruiting2 awardsPhase 3
Burbank, California
This trial is comparing a combination of MK-2870 and pembrolizumab to just pembrolizumab alone to see which one is better for overall survival. Participants who have completed the
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service